Cerus’ Post

View organization page for Cerus, graphic

9,453 followers

While fibrinogen is generally recognized as a critical blood clotting factor that can decline quickly in the massive hemorrhage patient, logistical challenges often prevent its rapid administration. Earlier this month, the American Journal of Clinical Pathology published the experience of Dr. Sethapati et al. with the implementation of pathogen reduced cryoprecipitated fibrinogen complex (commonly referred to as INTERCEPT Fibrinogen Complex) at Stanford Health Care’s Blood Bank. The publication, which details the positive impact of this blood product on waste and turnaround time at a single site, can be found here: https://ow.ly/HBIp50SAsrU #massivehemorrhage #transfusion #fibrinogen

Implementation and early outcomes with Pathogen Reduced Cryoprecipitated Fibrinogen Complex

Implementation and early outcomes with Pathogen Reduced Cryoprecipitated Fibrinogen Complex

academic.oup.com

Jason Gillihan MD, MBA

Chief Medical Officer, Barnes-Jewish West County Hospital

2mo

Great product! We have transitioned our entire cryo inventory at Washington University in St. Louis to Cerus IFC. It was a game changer in my last trauma resuscitation.

Breakthrough technology!

See more comments

To view or add a comment, sign in

Explore topics